Literature DB >> 15705476

Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals.

Beatriz P Quiambao1, Efren M Dimaano, Cristina Ambas, Rolan Davis, Angelika Banzhoff, Claudius Malerczyk.   

Abstract

Purified chick embryo cell rabies vaccine (PCECV) administered as 0.1 ml intradermally according to the Thai Red Cross (TRC) regimen could reduce the cost of PEP by up to 84% when compared to the traditional five-dose Essen regimen. To confirm the efficacy of 0.1 ml of PCECV using the TRC regimen, a clinical trial was conducted in 113 patients presenting with category III exposures from confirmed rabid animals at two bite referral centres in the Philippines. Patients were monitored monthly for 1 year after exposure. PCECV was well tolerated, no vaccine-related serious adverse events occurred and all patients were alive 1 year after their initial exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705476     DOI: 10.1016/j.vaccine.2004.09.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Molecular and immunogenic characterization of BHK-21 cell line adapted CVS-11 strain of rabies virus and future prospect in vaccination strategy.

Authors:  Arunkumar C Patel; Vikramaditya Upmanyu; Santhamani Ramasamy; Praveen Kumar Gupta; Rajendra Singh; Rabindra Prasad Singh
Journal:  Virusdisease       Date:  2015-11-19

2.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Authors:  Ashwath Narayana; Aravind Manoharan; Madhusudana Shampur Narayan; Sudarshan Mysore Kalappa; Gangaboraiah Biligumba; Ravish Haradanahalli; Ashwini Manoor Anand
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Authors:  Yotam Levin; Efrat Kochba; Ivan Hung; Richard Kenney
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa.

Authors:  Alyssa M Bilinski; Meagan C Fitzpatrick; Charles E Rupprecht; A David Paltiel; Alison P Galvani
Journal:  Proc Biol Sci       Date:  2016-11-16       Impact factor: 5.349

7.  Case report: An unusual case of priapism.

Authors:  S Depani; E M Molyneux
Journal:  Malawi Med J       Date:  2012-03       Impact factor: 0.875

Review 8.  Intradermal vaccination for infants and children.

Authors:  Akihiko Saitoh; Yuta Aizawa
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

9.  Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania.

Authors:  Eunha Shim; Katie Hampson; Sarah Cleaveland; Alison P Galvani
Journal:  Vaccine       Date:  2009-11-27       Impact factor: 3.641

10.  Rabies situation in Cambodia.

Authors:  Sowath Ly; Philippe Buchy; Nay Yim Heng; Sivuth Ong; Nareth Chhor; Hervé Bourhy; Sirenda Vong
Journal:  PLoS Negl Trop Dis       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.